KALY - New Cannabis Biotech On Scene With Near Term PPS Potential To $0.10
Print
Alert
New York, NY -- December 21, 2018 -- InvestorsHub NewsWire -- Kali, Inc. (USOTC: KALY) executed a reverse merger last month acquiring a patented cannabis extraction asset. As the company cleans up its filings and updates its website, it is becoming clear that there is a lot here under the hood. Not only does the company have a patented cannabis extraction process, it has a substantial amount of research behind cannabis extracts derived from the patented extraction process. The company just release news this week (see below) on research conducted with Beach Tree Labs and Brown University for a cannabis extract therapy for respiratory diseases. This research was intended as an example of more research yet to be disclosed. The news indicated further research study information would be forthcoming. The company has already attracted the attention of Generex Biotechnology (OTCQB: GNBT) that has FDA trials underway with the likes of Merck (NYSE: MRK). If KALY’s partnership with GNBT advances to trial stage or if GNBT signs a second pharmaceutical company, KALY can arguably justify a $100 million valuation and $0.10 PPS. Even now, with preclinical research results for a respiratory condition with an $11 billion therapy market, where a 1 percent penetration of that market would be over $1 billion dollars, KALY can justify a higher valuation today than the current PPS. Comparing KALY to other OTC quoted biotechs; taking into account the OTC transparency concerns, but also considering the $400,000 in revenue contracts (see below) KALY has recently announced, a $0.05 PPS today does not seem out of the question.
KALY Highlights:
Kali-Extracts, Inc. Releases Preclinical Research Study Results on Therapy for Respiratory Disease Driving $11 Billion Treatment Market
Kali-Extracts Inc. Announces $300,000 Contract to Produce Hemp-Derived CBD Extract for Puration Inc.
KALY - Kali-Extracts Announces $100,000 Order of its Hemp4mula CBD Infused Chewing Gum Available Soon on USMJ E-commerce Site
Kali-Extracts and Nouveau Announce 100 Acer Hemp Farm and CBD Extraction Facility Made Possible By New Farm Bill
KALY Short Squeeze
The KALY PPS has gone in the last month from $0.003 to over $0.03. As with any such meteoric, the trading has attracted its fair share of short sellers. In fact, KALY has been reported all week as one of the top 11 most shorted stocks on the OTC. Yesterday, the PPS dropped below $0.02 as a result of a short raid, but not on a lot of volume. The PPS popped at the open today almost going back to $0.03. There is definitely a short squeeze here and if all that KALY has under the hood gets a little more market attention, the short cover will contribute to pushing the KALY PPS to the $0.05 it arguably deserves today and maybe even higher.
